SCHEMBL2473359

SCHEMBL2473359

CC(C)c1cccnc1C1CC(=O)CC(c2ncccc2C(C)C)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.43
TAAR1 Q96RJ0 2/20 0.34
TNKS2 Q9H2K2 2/20 0.32
TNKS O95271 1/20 0.32
GSK3B P49841 1/20 0.32
SYK P43405 2/20 0.32
CXCR4 P61073 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRB2 P47870 1/20 0.31
NISCH Q9Y2I1 1/20 0.31
IDH1 O75874 1/20 0.31
KMT2A Q03164 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
ADORA2A P29274 1/20 0.30
ADORA1 P30542 1/20 0.30
ALOX15 P16050 1/20 0.30
HCAR1 Q9BXC0 1/20 0.30
HTR1A P08908 1/20 0.30
DRD2 P14416 1/20 0.30
HTR7 P34969 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2475176 1.00 CHRNA7 (0.43) CHRNA7TAAR1TNKS2TNKSGSK3B
SCHEMBL2472927 0.81 CHRNA7 (0.42) CHRNA7TAAR1CXCR4GABRA1GABRB2
SCHEMBL15237607 0.80 NOS3 (0.36) TNKS2GSK3BKMT2AADORA3ADORA2A
SCHEMBL4244126 0.80 NOS3 (0.36) TNKS2GSK3BKMT2AADORA3ADORA2A
SCHEMBL2473509 0.80 NOS3 (0.36) TNKS2GSK3BKMT2AADORA3ADORA2A
SCHEMBL2609321 0.72 CHRNA7 (0.47) CHRNA7CXCR4GABRA1GABRB2
SCHEMBL13439542 0.69 CHRNA7 (0.45) CHRNA7CXCR4GABRA1GABRB2
SCHEMBL2472143 0.68
SCHEMBL5574831 0.68
SCHEMBL21974223 0.68 CHRNA7 (0.44) CHRNA7CXCR4GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2664617-A1 Method of making a 2,6-diaryl piperidine derivative Genzyme Corporation (US) 2013-11-20 EP disclosed
EP-1615633-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY GENZYME CORP (US) 2012-08-15 EP disclosed
EP-2374804-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy Genzyme Corporation (US) 2011-10-12 EP disclosed
US-7550484-B2 Chemokine receptor binding heterocyclic compounds with enhanced efficacy GENZYME CORPORATION (US) 2009-06-23 US disclosed
US-7501518-B2 Methods of making 2,6-diaryl piperidine derivatives GENZYME CORPORATION (US) 2009-03-10 US disclosed
US-20050154201-A1 Methods of making 2,6-diaryl piperidine derivatives ANORMED CORPORATION (CA) 2005-07-14 US disclosed
US-20050059702-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy ANORMED CORPORATION (CA) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154201-A1 Methods of making 2,6-diaryl piperidine derivatives ALDH7A1, DPYD, ALDH1A1 CHRNA7 3082/4885TAAR1 641/4885TNKS2 895/4885
US-20050059702-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy CXCR4, CXCR1, CCR5 CHRNA7 914/4885TAAR1 1199/4885TNKS2 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.